{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:46:05Z","timestamp":1791924365932,"version":"4.3.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100024580","name":"Orion Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024580","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In advanced heart failure (AdHF), repeated levosimendan infusions between 0.1 and 0.2\u00a0\u03bcg\/kg\/min for 6\u201324\u00a0h every 2\u20134\u00a0weeks were associated with inconsistent outcomes and trends towards worse prognosis. Treatment effect with lower dosing is however unknown. The aims of this retrospective study were to assess the impact of 24-h levosimendan cycles at 0.05\u00a0\u03bcg\/kg\/min every 4\u00a0weeks on HF therapy, outcomes, and safety and to identify predictors of treatment efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Among 286 AdHF patients, 39 levosimendan-treated subjects (4.19\u2009\u00b1\u20092.6 infusions) and 39 standard-of-care (SOC) subjects matched 1:1 based on a propensity score accounting for age, sex, ischemic heart disease, left ventricular (LV) ejection fraction, creatinine, heart rhythm, and heart transplantation (HTx) listing underwent comparison of their outcome. Efficacy was defined as 1-year survival without LV-assist-device, urgent HTx and urgent hospitalization for HF. Adverse events (AE) included permanent levosimendan interruption, sustained arrhythmias, or hypotension occasioning permanent infusion hold.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Beta-blocker (BB) dose increased with levosimendan [34.7% (18.4\u201350%) of target-dose at 6-months vs. 21.9% (6.25\u201325%) at baseline (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.022)]. At 1\u00a0year, 26 patients reached the efficacy endpoint in the levosimendan group vs. 14 in the SOC group (HR\u2009=\u20090.42; 95% CI\u2009=\u20090.22\u20130.83;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.01). The benefit of levosimendan was essentially driven by the reduction of HF hospitalization (HR\u2009=\u20090.367; 95% CI\u2009=\u20090.16\u20130.85;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.014), with no difference in the reduction of death, LVAD or SU-HTx (HR\u2009=\u20090.8; 95% CI\u2009=\u20090.3\u201321.4;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.65). No AE occurred. We found no prognostic factor at baseline but BB therapy (95.6% vs. 50%;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.005), higher BB dosing (33\u2009\u00b1\u200920% vs. 9\u2009\u00b1\u200920% of target-dose;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.036), and lower heart rate (71\u2009\u00b1\u200910.4 vs. 81\u2009\u00b1\u200914\u00a0bpm;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.039) at 3\u00a0months were associated with treatment efficacy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings raise the hypotheses that low-dose levosimendan is safe, enables BB up-titration, and is associated with improved outcomes. Heart rate, BB therapy, and BB dosing at 3\u00a0months may predict event-free survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00392-026-02945-z","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T13:00:26Z","timestamp":1780491626000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Low-dose levosimendan infusions in advanced heart failure: efficacy, safety, and factors associated with outcomes"],"prefix":"10.1007","author":[{"given":"Nicolas","family":"Barras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kiko\u00efne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Liaudet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Sotiropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Regamey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Godinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Hullin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8163-722X","authenticated-orcid":false,"given":"Patrick","family":"Yerly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"2945_CR1","doi-asserted-by":"crossref","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, Burri H, Butler J, \u010celutkien\u0117 J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A, ESC Scientific Document Group (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42(36):3599\u20133726","DOI":"10.1093\/eurheartj\/ehab670"},{"key":"2945_CR2","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jchf.2020.01.014","volume":"8","author":"L Truby","year":"2020","unstructured":"Truby L, Rogers J (2020) Advanced heart failure. Epidemiology, diagnosis and therapeutic approaches. State-of-the-art review. JACC Heart Fail 8:523\u2013536","journal-title":"JACC Heart Fail"},{"key":"2945_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ijcard.2019.09.005","volume":"297","author":"D Farmakis","year":"2019","unstructured":"Farmakis D, Agostoni P, Baholli L, Bautin A, Comin-Colet J, Crespo-Leiro MG, Fedele F, Garc\u00eda-Pinilla JM, Giannakoulas G, Grigioni F, Grucha\u0142a M, Gustafsson F, Harjola VP, Hasin T, Herpain A, Iliodromitis EK, Karason K, Kivikko M, Liaudet L, Ljubas-Ma\u010dek J, Marini M, Masip J, Mebazaa A, Nikolaou M, Ostadal P, P\u00f5der P, Pollesello P, Polyzogopoulou E, P\u00f6lzl G, Tschope C, Varpula M, von Lewinski D, Vrtovec B, Yilmaz MB, Zima E, Parissis J (2019) A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: an expert panel consensus. Int J Cardiol 297:83\u201390","journal-title":"Int J Cardiol"},{"key":"2945_CR4","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/ejhf.2814","volume":"4","author":"F Gustafsson","year":"2023","unstructured":"Gustafsson F, Damman K, Nalbantgil S, Van Laake LW, Tops LF, Thum T, Adamopoulos S, Bonios M, Coats AJ, Crespo-Leiro MG, Mehra MR, Filippatos G, Hill L, Metra M, Jankowska E, de Jonge N, Kaye D, Masetti M, Parissis J, Milicic D, Seferovic P, Rosano G, Ben Gal T (2023) Inotropic therapy in patients with advanced heart failure. A clinical consensus statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 4:457\u2013468","journal-title":"Eur J Heart Fail"},{"key":"2945_CR5","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S0002-8703(99)70250-4","volume":"138","author":"CM O\u2019Connor","year":"2000","unstructured":"O\u2019Connor CM, Gattis WA, Uretsky BF (2000) Continuous intravenous dobutamine in associated with an increased risk of death in patients with advanced heart failure: Insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 138:78\u201386","journal-title":"Am Heart J"},{"key":"2945_CR6","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00134-011-2435-6","volume":"38","author":"CL Tacon","year":"2012","unstructured":"Tacon CL, McCaffrey J, Delaney A (2012) Dobutamine for patients with severe heart failure: a systematic review and meta-analysis of randomised controlled trials. Intensive Care Med 38:359\u2013367","journal-title":"Intensive Care Med"},{"key":"2945_CR7","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1056\/NEJM199111213252103","volume":"325","author":"M Packer","year":"1991","unstructured":"Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML (1991) Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 325:1468\u201375","journal-title":"N Engl J Med"},{"key":"2945_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ejphar.2003.12.005","volume":"486","author":"S Szil\u00e1gyi","year":"2004","unstructured":"Szil\u00e1gyi S, Pollesello P, Levijoki J, Kaheinen P, Haikala H, Edes I, Papp Z (2004) The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig. Eur J Pharmacol 486:67\u201374","journal-title":"Eur J Pharmacol"},{"key":"2945_CR9","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.ijcard.2016.07.202","volume":"222","author":"D Farmakis","year":"2016","unstructured":"Farmakis D, Alvarez J, Gal T, Brito D, Fedele F, Fonseca C, Gordon A, Gotsman I, Grossini E, Guarracino F, Harjola V, Hellman Y, Heunks L, Ivancan V, Karavidas A, Kivikko M, Lomivorotov V, Longrois D, Masip J, Metra M, Morelli A, Nikolaou M, Papp Z, Parkhomenko A, Poelzl G, Pollesello P, Berg Ravn H, Rex S, Riha H, Ricksten S, Schwinger R, Vrtovec B, Yilmaz M, Zielinska M, Parissis J (2016) Levosimendan beyond inotropy and acute heart failure: evidence of pleiotropic effects on the heart and other organs: an expert panel position paper. Int J Cardiol 222:303\u2013312","journal-title":"Int J Cardiol"},{"key":"2945_CR10","first-page":"1768","volume":"92","author":"JT Parissis","year":"2006","unstructured":"Parissis JT, Adamopoulos S, Farmakis D, Filippatos G, Paraskevaidis I, Panou F, Iliodromitis E, Kremastinos DT (2006) Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure. Heart 92:1768\u201372","journal-title":"Heart"},{"key":"2945_CR11","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.cardfail.2007.04.004","volume":"13","author":"S Mavrogeni","year":"2007","unstructured":"Mavrogeni S, Giamouzis G, Papadopoulou E, Thomopoulou S, Dritsas A, Athanasopoulos G, Adreanides E, Vassiliadis I, Spargias K, Panagiotakos D, Cokkinos DV (2007) A 6-month follow-up of intermittent levosimendan administration effect on systolic function, specific activity questionnaire, and arrhythmia in advanced heart failure. J Card Fail 13:556\u2013559","journal-title":"J Card Fail"},{"key":"2945_CR12","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1097\/FJC.0b013e31826b86aa","volume":"60","author":"G Malfatto","year":"2012","unstructured":"Malfatto G, Della Rosa F, Villani A, Rella V, Branzi G, Facchini M, Parati G (2012) Intermittent levosimendan infusions in advanced heart failure: favourable effects on left ventricular function, neurohormonal balance, and one-year survival. J Cardiovasc Pharmacol 60:450\u2013455","journal-title":"J Cardiovasc Pharmacol"},{"key":"2945_CR13","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1177\/0300060516655244","volume":"45","author":"B Ortis","year":"2017","unstructured":"Ortis B, Villani A, Oldani M, Giglio A, Ciambellotti F, Facchini M, Parati G, Malfatto G (2017) Intermittent levosimendan infusions in advanced heart failure: A real world experience. J Int Med Res 45:361\u2013371","journal-title":"J Int Med Res"},{"key":"2945_CR14","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ejheart.2006.06.001","volume":"9","author":"R Berger","year":"2007","unstructured":"Berger R, Moertl D, Huelsmann M, Bojic A, Ahmadi R, Heissenberger I, Pacher R (2007) Levosimendan and prostaglandin E1 for uptitration of beta-blockade in patients with refractory, advanced chronic heart failure. Eur J Heart Fail 9:202\u2013208","journal-title":"Eur J Heart Fail"},{"key":"2945_CR15","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1002\/ejhf.118","volume":"16","author":"J Altenberger","year":"2014","unstructured":"Altenberger J, Parissis JT, Costard-Jaeckle A, Winter A, Ebner C, Karavidas A, Sihorsch K, Avgeropoulou E, Weber T, Dimopoulos L, Ulmer H, Poelzl G (2014) Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial. Eur J Heart Fail 16:898\u2013906","journal-title":"Eur J Heart Fail"},{"key":"2945_CR16","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/ejhf.1145","volume":"20","author":"J Com\u00edn-Colet","year":"2018","unstructured":"Com\u00edn-Colet J, Manito N, Segovia-Cubero J, Delgado J, Garc\u00eda Pinilla JM, Almenar L, Crespo-Leiro MG, Sionis A, Blasco T, Pascual-Figal D, Gonzalez-Vilchez F, Lambert-Rodr\u00edguez JL, Grau M, Bruguera J, LION-HEART Study Investigators (2018) Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial. Eur J Heart Fail 20:1128\u20131136","journal-title":"Eur J Heart Fail"},{"key":"2945_CR17","doi-asserted-by":"publisher","first-page":"4820","DOI":"10.1002\/ehf2.13670","volume":"8","author":"MJ Garc\u00eda-Gonz\u00e1lez","year":"2021","unstructured":"Garc\u00eda-Gonz\u00e1lez MJ, Aldea Perona A, Lara Padron A, Morales Rull JL, Mart\u00ednez-Sell\u00e9s M, de Mora Martin M, L\u00f3pez D\u00edaz J, L\u00f3pez Fernandez S, Ortiz Oficialdegui P, Jim\u00e9nez Sosa A (2021) Efficacy and safety of intermittent repeated levosimendan infusions in advanced heart failure patients: the LAICA study. ESC Heart Failure 8:4820\u20134831","journal-title":"ESC Heart Failure"},{"key":"2945_CR18","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1002\/ejhf.3006","volume":"11","author":"G P\u00f6lzl","year":"2023","unstructured":"P\u00f6lzl G, Altenberger J, Com\u00edn-Colet J, Delgado JF, Fedele F, Garc\u00eda-Gonz\u00e1lez MJ, Gustafsson F, Masip J, Papp Z, St\u00f6rk S, Ulmer H, Maier S, Vrtovec B, Wikstr\u00f6m G, Zima E, Bauer A, LeoDOR Investigators (2023) Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period: the multinational randomized LeoDOR trial. Eur J Heart Fail 11:2007\u20132017","journal-title":"Eur J Heart Fail"},{"key":"2945_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14278","author":"D Dobarro","year":"2023","unstructured":"Dobarro D, Donoso-Trenado V, Sol\u00e9-Gonz\u00e1lez E, Moliner-Ab\u00f3s C, Garcia-Pinilla JM, Lopez-Fernandez S, Ruiz-Bustillo S, Diez-Lopez C, Castrodeza J, M\u00e9ndez-Fern\u00e1ndez AB, Vaqueriza-Cubillo D, Cobo-Marcos M, Tobar J, Sagasti-Aboitiz I, Rodriguez M, Escolar V, Abecia A, Codina P, G\u00f3mez-Otero I, Pastor F, Marzoa-Rivas R, Gonz\u00e1lez-Babarro E, de Juan-Baguda J, Melendo-Viu M, de Frutos F, Gonzalez-Costello J (2023) Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: the LEVO-D registry. ESC Heart Fail. https:\/\/doi.org\/10.1002\/ehf2.14278","journal-title":"ESC Heart Fail"},{"key":"2945_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1236","author":"MG Crespo-Leiro","year":"2018","unstructured":"Crespo-Leiro MG, Metra M, Lund LH, Milicic D, Costanzo MR, Filippatos G, Gustafsson F, Tsui S, Barge-Caballero E, De Jonge N, Frigerio M, Hamdan R, Hasin T, H\u00fclsmann M, Nalbantgil S, Potena L, Bauersachs J, Gkouziouta A, Ruhparwar A, Ristic AD, Straburzynska-Migaj E, McDonagh T, Seferovic P, Ruschitzka F (2018) Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. https:\/\/doi.org\/10.1002\/ejhf.1236","journal-title":"Eur J Heart Fail"},{"key":"2945_CR21","first-page":"I11","volume":"Supplement I","author":"F Oliva","year":"2018","unstructured":"Oliva F, Comin-Colet J, Fedele F, Fruhwald F, Gustafsson F, Kivikko M, Borb\u00e9ly A, P\u00f6lzl G, Tsch\u00f6pe C (2018) Repetitive levosimendan treatment in the management of advanced heart failure. EHJ Supplement I:I11\u2013I20","journal-title":"EHJ"},{"key":"2945_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11216408","volume":"11","author":"D Masarone","year":"2022","unstructured":"Masarone D, Kittleson MM, Pollesello P, Marini M, Iacoviello M, Oliva F, Caiazzo A, Petraio A, Pacileo G (2022) Use of levosimendan in patients with advanced heart failure: an update. J Clin Med 11:6408","journal-title":"J Clin Med"},{"key":"2945_CR23","doi-asserted-by":"publisher","unstructured":"Oliva F, Perna E, Marini M, Nassiacos D, Cir\u00f2 A, Malfatto G, Morandi F, Caico I, Perna G, Meloni S, Vincenzi A, Villani A,Vecchi AL, Minoia C, Verde A, De Maria R, RELEVANT-HF study group (2018) Scheduled intermittent inotropes for ambulatory advanced heart failure. The RELEVANT-HF multicentre collaboration. Int J Cardiol 272:255\u2013259. https:\/\/doi.org\/10.1016\/j.ijcard.2018.08.048","DOI":"10.1016\/j.ijcard.2018.08.048"},{"key":"2945_CR24","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1161\/CIRCULATIONAHA.107.696906","volume":"116","author":"SD Solomon","year":"2007","unstructured":"Solomon SD, Dobson J, Pocock S, Skali H, McMurray JJ, Granger CB, Yusuf S, Swedberg K, Young JB, Michelson EL, Pfeffer MA, Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Investigators (2007) Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 116:1482\u20131487","journal-title":"Circulation"},{"key":"2945_CR25","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S0140-6736(02)09455-2","volume":"360","author":"F Follath","year":"2002","unstructured":"Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, Lehtonen L, Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study (2002) Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 360:196\u2013202","journal-title":"Lancet"},{"key":"2945_CR26","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1001\/jama.297.17.1883","volume":"297","author":"A Mebazaa","year":"2007","unstructured":"Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, P\u00f5der P, Kivikko M, SURVIVE Investigators (2007) Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA 297:1883\u20131891","journal-title":"JAMA"},{"key":"2945_CR27","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/ehf2.12091","volume":"3","author":"K Sotiropoulos","year":"2016","unstructured":"Sotiropoulos K, Yerly P, Monney P, Garnier A, Regamey J, Hugli O, Martin D, Metrich M, Antonietti JP, Hullin R (2016) Red cell distribution width and mortality in acute heart failure patients with preserved and reduced ejection fraction. ESC Heart Fail 3:198\u2013204","journal-title":"ESC Heart Fail"},{"key":"2945_CR28","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1001\/archinte.168.13.1371","volume":"168","author":"JS Ross","year":"2008","unstructured":"Ross JS, Mulvey GK, Stauffer B, Patlolla V, Bernheim SM, Keenan PS, Krumholz HM (2008) Statistical models and patient predictors of readmission for heart failure: a systematic review. Arch Intern Med 168:1371\u20131386","journal-title":"Arch Intern Med"},{"key":"2945_CR29","volume-title":"Statistical power analysis for the behavioral sciences","author":"J Cohen","year":"1988","unstructured":"Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd ed. Lawrence Erlbaum, Hillsdale, NJ","edition":"2nd ed"},{"key":"2945_CR30","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.ijcard.2017.05.081","volume":"243","author":"G P\u00f6lzl","year":"2017","unstructured":"P\u00f6lzl G, Altenberger J, Baholli L, Beltr\u00e1n P, Borb\u00e9ly A, Comin-Colet J, Delgado JF, Fedele F, Fontana A, Fruhwald F, Giamouzis G, Giannakoulas G, Garcia-Gonz\u00e1lez MJ, Gustafsson F, Kaikkonen K, Kivikko M, Kubica J, von Lewinski D, L\u00f6fman I, Malfatto G, Manito N, Mart\u00ednez-Sell\u00e9s M, Masip J, Merkely B, Morandi F, M\u00f8lgaard H, Oliva F, Pantev E, Papp Z, Perna GP, Pfister R, Piazza V, Bover R, Rangel-Sousa D, Recio-Mayoral A, Reinecke A, Rieth A, Sarapohja T, Schmidt G, Seidel M, St\u00f6rk S, Vrtovec B, Wikstr\u00f6m G, Yerly P, Pollesello P (2017) Repetitive use of levosimendan in advanced heart failure: need for stronger evidence in a field in dire need of a useful therapy. Int J Cardiol 243:389\u2013395","journal-title":"Int J Cardiol"},{"key":"2945_CR31","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1002\/ejhf.3054","volume":"25","author":"F Castagna","year":"2023","unstructured":"Castagna F, Simitsis P, Mehra MR (2023) Overcoming vulnerability in heart failure: transitional tactical toughness. Eur J Heart Fail 25:2018\u20132020","journal-title":"Eur J Heart Fail"},{"issue":"19","key":"2945_CR32","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1161\/CIRCULATIONAHA.118.039331","volume":"139","author":"DA Morrow","year":"2019","unstructured":"Morrow DA, Velazquez EJ, DeVore AD, Desai AS, Duffy CI, Ambrosy AP, Gurmu Y, McCague K, Rocha R, Braunwald E (2019) Clinical outcomes in patients with acute decompensated heart failure randomly assigned to sacubitril\/valsartan or enalapril in the PIONEER-HF trial. Circulation 139(19):2285\u20132288. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.039331","journal-title":"Circulation"},{"key":"2945_CR33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1001\/jamacardio.2021.4567","volume":"7","author":"DL Mann","year":"2022","unstructured":"Mann DL, Givertz M, Vader J, Starling R, Shah P, McNulty S, Anstrom K, Margulies K, Kiernan M, Mahr C, Gupta D, Redfield M, Lala A, Lewis G, DeVore A, Desvigne-Nickens P, Hernandez A, Braunwald E, LIFE Investigators (2022) Effect of treatment with sacubitril\/valsartan in patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA Cardiol 7:17\u201325","journal-title":"JAMA Cardiol"},{"key":"2945_CR34","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/S0140-6736(10)61259-7","volume":"376","author":"M B\u00f6hm","year":"2010","unstructured":"B\u00f6hm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, SHIFT Investigators (2010) Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 376:886\u201394","journal-title":"Lancet"},{"key":"2945_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11144227","volume":"11","author":"D Masarone","year":"2022","unstructured":"Masarone D, Kittleson MM, Martucci ML, Valente F, Gravino R, Verrengia M, Ammendola E, Contaldi C, Di Palma V, Caiazzo A, Petraio A, Pollesello P, Pacileo G (2022) Levosimendan as a \u201cbridge to optimization\u201d in patients with advanced heart failure with reduced ejection-a single-center study. J Clin Med 11:4227. https:\/\/doi.org\/10.3390\/jcm11144227","journal-title":"J Clin Med"},{"key":"2945_CR36","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/eurheartj\/ehx026","volume":"38","author":"W Ouwerkerk","year":"2017","unstructured":"Ouwerkerk W, Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Lang CC, Ter Maaten JM, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Metra M, Zwinderman AH (2017) Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur Heart J 38:1883\u20131890","journal-title":"Eur Heart J"},{"issue":"10367","key":"2945_CR37","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","volume":"400","author":"A Mebazaa","year":"2022","unstructured":"Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, Metra M, Ponikowski P, Sliwa K, Voors AA, Edwards C, Novosadova M, Takagi K, Damasceno A, Saidu H, Gayat E, Pang PS, Celutkiene J, Cotter G (2022) Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet 400(10367):1938\u20131952. https:\/\/doi.org\/10.1016\/S0140-6736(22)02076-1","journal-title":"Lancet"},{"key":"2945_CR38","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11897-014-0240-6","volume":"12","author":"E Joyce","year":"2015","unstructured":"Joyce E, Nohria A (2015) Therapeutic adjustments in stage D heart failure: challenges and strategies. Curr Heart Fail Rep 12:15\u201323","journal-title":"Curr Heart Fail Rep"},{"issue":"Supp 2","key":"2945_CR39","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1136\/hrt.79.2008.29S","volume":"79","author":"K Swedberg","year":"1998","unstructured":"Swedberg K (1998) History of beta blockers in congestive heart failure. Heart 79(Supp 2):S29-30","journal-title":"Heart"},{"issue":"10","key":"2945_CR40","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.ejheart.2008.08.005","volume":"10","author":"K Dickstein","year":"2008","unstructured":"Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Str\u00f6mberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K, ESC Committee for Practice Guidelines (CPG) (2008) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 10(10):933\u201389","journal-title":"Eur J Heart Fail"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-026-02945-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-026-02945-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-026-02945-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:02:29Z","timestamp":1791921749000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-026-02945-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":40,"alternative-id":["2945"],"URL":"https:\/\/doi.org\/10.1007\/s00392-026-02945-z","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"8 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article was originally published under the subscription model but it is now published under an Open Access license.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by our institutional ethics committee (CER-VD-244\/14) and complied with the declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was waived due to the retrospective nature of the study.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The last author (PY) was the recipient of an unrestricted research grant from Orion Pharma, Espoo, Finland. He also reports consulting for MSD, Johnson & Johnson, Bayer, Novartis, and Servier. JK received speaker\u2019s fees from AstraZeneca and Bristol Myers Squibb. The other authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}